Abstract
Aim: With the final aim to explore the first-line treatment options for non-small-cell lung cancer (NSCLC) patients, we performed a systematic review and literature-based meta-analysis of available clinical trials exploring immunotherapy in combination versus standard histology-based chemotherapy. Materials & methods: We evaluated interactions according to type of treatment-add-on strategy: immunotherapy in combination versus standard chemotherapy-based regimens. Hazard ratio (HR) for overall survival (OS) and progression-free survival (PFS) were extracted and cumulated. Results: Seven trials (4278 patients) were included. The addition of immunotherapy to standard chemotherapy-based regimens significantly increased OS (HR 0.74; p = 0.001) and PFS (HR 0.61; p < 0.0001) compared with standard-of-care in NSCLC patients in first-line setting. Conclusion: Immunotherapy-based regimens constantly improved OS and PFS compared with chemotherapy in first-line treatment of nononcogene-addicted NSCLC.
Lingua originale | English |
---|---|
pagine (da-a) | 921-930 |
Numero di pagine | 10 |
Rivista | Immunotherapy |
Volume | 11 |
DOI | |
Stato di pubblicazione | Pubblicato - 2019 |
Keywords
- NSCLC
- PD-1
- PD-L1
- atezolizumab
- first line
- immunotherapy
- meta-analysis
- nivolumab
- pembrolizumab